SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

Saad Zafar Usmani, MD, shares the “unprecedented” results from the phase II trial of the anti-CD38 monoclonal antibody daratumumab in patients with double refractory heavily pretreated multiple myeloma. Read more about SIRIUS here.

 

SHARE